Literature DB >> 21494197

The spine in β-thalassemia syndromes.

Rachid Haidar1, Hani Mhaidli, Khaled M Musallam, Ali T Taher.   

Abstract

STUDY
DESIGN: Literature review.
OBJECTIVE: To present a comprehensive overview of spinal involvement in patients with β-thalassemia, aiming to orient the spinal surgeon to these potentially disabling complications. SUMMARY OF BACKGROUND DATA: β-thalassemia, an inherited disorder of hemoglobin synthesis, is the most common monogenetic disease worldwide. Patients with thalassemia major (TM) suffer a severe anemia that requires regular blood transfusions for survival and iron chelation therapy to control transfusional iron overload. Thalassemia intermedia is a phenotype of thalassemia with a milder course and anemia, wherein most patients remain transfusion independent. Spinal involvement related to disease course and treatment is common in patients with thalassemia syndromes, yet it has not been constructively reviewed in the literature.
METHODS: Potentially relevant studies were identified from an electronic search of MEDLINE (1966 to the second week of May 2010).
RESULTS: In patients with TM, genetic and acquired risk factors lead to osteoporosis, pathologic fractures of the spine, and back pain. Osteoporosis in TM patients is progressive; thus, early diagnosis and treatment are recommended. Bisphosphonates are relatively safe and effective in this patient population. Characteristic intervertebral disc degeneration is also seen in patients with TM who have evidence of severe iron overload or those who receive the subcutaneous iron chelator deferoxamine. Spinal asymmetry and overt scoliosis are common in patients with TM. The prognosis seems favorable, with many patients showing spontaneous resolution without the need for intervention. In patients with thalassemia intermedia, ineffective erythropoiesis drives extramedullary hematopoietic tissue formation, which is mostly evident on magnetic resonance imaging. Paraspinal involvement is of greatest concern because of the associated spinal cord compression. Several treatment options have been described, including transfusion therapy, laminectomy, radiotherapy, and the use of fetal hemoglobin-inducing agents that decrease the hematopoietic drive.
CONCLUSION: Current knowledge supports that spinal involvement in patients with β-thalassemia is common and diverse yet still requires further prospective evaluation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21494197     DOI: 10.1097/BRS.0b013e31821bd095

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  6 in total

Review 1.  Musculoskeletal imaging manifestations of beta-thalassemia.

Authors:  Maryam Hajimoradi; Sara Haseli; Alireza Abadi; Majid Chalian
Journal:  Skeletal Radiol       Date:  2021-02-09       Impact factor: 2.199

Review 2.  Iron homeostasis in osteoporosis and its clinical implications.

Authors:  G F Li; Y Z Pan; P Sirois; K Li; Y J Xu
Journal:  Osteoporos Int       Date:  2012-04-14       Impact factor: 4.507

Review 3.  Assessment and treatment of pain in thalassemia.

Authors:  Ashutosh Lal
Journal:  Ann N Y Acad Sci       Date:  2016-04-28       Impact factor: 5.691

4.  Physiopathology of Bone Modifications in β-Thalassemia.

Authors:  Carlo Perisano; Emanuele Marzetti; Maria Silvia Spinelli; Cinzia Anna Maria Callà; Calogero Graci; Giulio Maccauro
Journal:  Anemia       Date:  2012-05-30

5.  Effects of iron overload on the bone marrow microenvironment in mice.

Authors:  Yuchen Zhang; Wenjing Zhai; Mingfeng Zhao; Deguan Li; Xiao Chai; Xiaoli Cao; Juanxia Meng; Jie Chen; Xia Xiao; Qing Li; Juan Mu; Jichun Shen; Aimin Meng
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

Review 6.  Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.

Authors:  Rayan Bou-Fakhredin; Abdul-Hamid Bazarbachi; Bachar Chaya; Joseph Sleiman; Maria Domenica Cappellini; Ali T Taher
Journal:  Int J Mol Sci       Date:  2017-12-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.